A new white paper from BioDlink, From Complexity to Consistency: How CDMOs Can Unlock One-Step, High-Yield and Homogeneous ...
Antibody Drug Conjugates (ADCs) are a class of small molecule drugs (also known as a payload) and an antibody conjugated together by a chemical linker. ADCs are designed to target specific cells, such ...
Vertical integration for CDMOs in manufacturing ADCs offers an opportunity to reduce costs and create a more resilient supply ...
With the precision of monoclonal antibodies and the potency of small-molecular payloads, antibody-drug conjugates (ADC) are promising cancer therapeutics. As of this year, there are 19 ADC drugs ...
Discover the top 3 manufacturing mistakes CDMOs make and how to prevent them when scaling for next-generation oncology.
Antibody-drug conjugates (ADCs) are typically composed of a monoclonal antibody attached to a cytotoxic drug via a chemical linker. The antibody is able to identify biomarkers on and attach to cancer ...
As pharmaceutical companies embrace antibody-drug conjugates (ADCs) as a way to treat cancer, drug services providers are investing in capacity to meet the companies’ manufacturing needs.
PRINCETON, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (SONN), a clinical-stage company developing targeted immunotherapeutic drugs, today announced its plans to ...
Unchained Labs, the life sciences company that's all about getting biologics and gene therapy researchers the right tool for the job, just launched a brand-new application on Stunner today that ...
OBI Pharma and TegMine Therapeutics Sign Exclusive Global License Agreement for Glycan-Targeting ADC
Successful Delivery of Commissioned ADC Candidate to Advance the Collaboration Between OBI and TegMine TAIPEI, TW / ...
Merck MRK announced that the FDA has granted the Breakthrough Therapy designation (BTD) to its B7-H3-directed DXd antibody-drug conjugate (ADC), ifinatamab deruxtecan (I-DXd), for treating adult ...
Merck (MRK) and its Japanese partner Daiichi Sankyo announced that the FDA has granted Breakthrough Therapy Designation ("BTD") to their investigational pipeline candidate, raludotatug deruxtecan ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results